Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) and Electra Vehicles, Inc. announced the filing of Amendment No. 1 to their Form S-4 registration statement regarding their previously announced merger. The filing provides a status update on the pending business combination, which is expected to close in the first quarter of 2027, and notes that Electra has raised $5 million in bridge financing.
Live Oak Acquisition Corp. VI announced that holders of units issued in its initial public offering may elect to separately trade the underlying Class A ordinary shares and warrants starting November 13, 2026. The separated securities will trade on Nasdaq under the symbols 'LOVI' and 'LOVIW', while unseparated units will continue to trade under 'LOVIU'. This is a standard post-IPO administrative step for SPACs to facilitate independent trading of equity and warrants.
Nuveen Farmland REIT M&A Deal with Teachers Insurance and Annuity Association of America
Nuveen Farmland REIT filed an amendment to provide required audited and pro forma financial statements for its September 24, 2026, acquisition of two agricultural properties in Mississippi and Illinois. The properties were acquired from a subsidiary of the company's sponsor, TIAA. The filing includes combined statements of revenues and operating expenses for the acquired assets for the year 2025 and the first half of 2026.
Counterparty
Teachers Insurance and Annuity Association of America (TIAA)
CorMedix Inc. has entered into a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics. The transaction will be funded in part through a new term loan facility with Pharmakon and the issuance of CorMedix common stock as consideration. The deal is expected to be accretive to earnings and free cash flow while providing operating cost synergies.
Perma-Pipe International Holdings Partnership with Welspun Corp Limited
Perma-Pipe International Holdings, through its subsidiary Perma-Pipe QA, has entered into a joint venture with Welspun Corp Limited to provide internal fusion bonded epoxy (IFBE) coating services in India. Perma-Pipe acquired a 51% controlling interest in the newly formed Welspun Special Coating Private Limited for a nominal cash consideration, while Welspun Corp holds the remaining 49%. The partnership aims to expand Perma-Pipe's global coating capabilities and establish a platform for domestic and export opportunities in the Indian market.
Forward Industries amended its at-the-market (ATM) equity offering program to add Barclays Capital Inc. as an additional sales agent alongside Cantor Fitzgerald. The program allows the company to sell up to $4 billion in common stock to fund its Solana (SOL) treasury strategy.
Novagold Resources M&A Deal with Paulson Advisers LLC
NOVAGOLD announced that the Supreme Court of British Columbia has approved its plan of arrangement to consolidate 100% ownership of the Donlin Gold project. The company will acquire the 40% interest held by Paulson Advisers LLC in an all-share transaction and establish a new U.S. parent company, NovaGold Corporation. The transaction is expected to close on December 1, 2026, with the new entity trading on the NYSE under the ticker 'NG' starting December 2.
Origin Tea Inc. completed a private placement of 290,000 shares of common stock to 115 non-U.S. purchasers in reliance on Regulation S. The company raised a total of RMB 11,600,000 (approximately RMB 40.00 per share) and granted the purchasers contractual resale registration rights.
Hecla Mining Company entered into an Equity Distribution Agreement to establish an at-the-market (ATM) offering program for up to 50 million shares of common stock. Additionally, the company announced the redemption of all outstanding Series B Cumulative Convertible Preferred Stock for approximately $7.64 million and reported that Russell D. Lawlar has been re-appointed as Principal Accounting Officer following the departure of Stuart Absolom.
Bunker Hill Silver M&A Deal with Silver47 Exploration Corp.
Bunker Hill Silver Corp. completed its acquisition of Silver47 Exploration Corp. via a court-approved plan of arrangement, making Silver47 a wholly owned subsidiary. Silver47 shareholders received 0.1724 Bunker Hill shares for each Silver47 share held, creating a combined U.S. silver and critical minerals producer with a pro forma market capitalization of approximately $158 million.
Counterparty
Silver47 Exploration Corp.
“This merger represents a transformational and timely opportunity to create a leading American mining company focused on strengthening the US domestic metal supply chains at a time of intensifying global competition. I congratulate all our shareholders and the wider stakeholder community for supporting this important step forward for the Combined Company, and its potential to contribute to the revitalization of the US Mining Industry.”
Richard Williams, Executive Chairman of Bunker Hill
“Bunker Hill and Silver47 shareholders now own a compelling silver and critical mineral story in the United States: a producing mine in the Silver Valley and a pipeline of high-grade projects at Red Mountain, Hughes and Mogollon. With silver on the U.S. critical minerals list and strong support for domestic mining, we have the assets, the team and the timing to build a leading American silver producer. Thank you to all our shareholders. We are excited to get to work.”
Galen McNamara, President and Chief Investment Officer of Bunker Hill
Rent the Runway received a deficiency notice from Nasdaq on November 4, 2026, because its market value of publicly held shares (MVPHS) fell below the $15 million minimum requirement for 39 consecutive business days. The company has 180 calendar days, until May 3, 2027, to regain compliance by maintaining a MVPHS of at least $15 million for ten consecutive business days. The company is evaluating options to resolve the deficiency, including a potential transfer to The Nasdaq Capital Market.
InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.
The Crypto Company entered into subscription agreements to sell 84,210,128 shares of common stock for an aggregate purchase price of $65,000. The consideration consisted of $50,000 in cash plus 1.4 ETH and 0.16 BTC. One of the investors, Three Mile Creek Future LLC, is managed by the company's Chief Strategy Officer, Rafael Furst.
Senti Biosciences entered into an equity commitment letter with CPIF II-9 Limited, an affiliate of Celadon Partners, for the purchase of up to $4.55 million of common stock. The commitment is structured to be funded in quarterly tranches through December 31, 2027, at a price per share based on Nasdaq's Minimum Price definition. The company also agreed to provide the investor with customary demand and piggyback registration rights for the shares issued.
World Omni Auto Receivables Trust 2026-D Capital Raise of $971M
World Omni Auto Receivables Trust 2026-D entered into an underwriting agreement to issue $970.86 million in asset-backed notes. The offering includes multiple classes of notes (Class A-1 through Class C) secured by motor vehicle retail installment sale contracts. The notes are expected to be issued on November 18, 2026, with Truist Securities, Mizuho, TD Securities, and Wells Fargo acting as representatives for the underwriters.
NextNRG, Inc. received notice that the Nasdaq Hearings Panel denied its request to continue its listing on Nasdaq due to failure to meet the $1.00 minimum bid price and $35 million market value requirements. Trading of the company's common stock will be suspended on November 11, 2026, and is expected to transition to the OTC Markets under the symbol 'NXXT'.
Golden Minerals completed a non-brokered private placement of 17.8 million units for gross proceeds of C$5.0 million. Each unit consists of one common share and one-half of a purchase warrant exercisable at C$0.45. Proceeds will fund exploration programs at the Desierto project in Argentina and general working capital through 2027.
Sino Green Land M&A Deal with Xing Da Plastics Sdn. Bhd.
Sino Green Land Corporation filed this amendment to provide required historical audited financial statements and pro forma financial information following its completed acquisition of three entities: Xing Da Plastics Sdn. Bhd., Invent Fortune Sdn. Bhd., and Hi-Quality Productions Inc. The filing serves as a status and regulatory update to the original merger reports filed in September and November 2026.
Counterparty
Xing Da Plastics Sdn. Bhd., Invent Fortune Sdn. Bhd., and Hi-Quality Productions Inc.
Alzamend Neuro entered into an Amended and Restated Securities Purchase Agreement with Ault Lending, LLC to sell $10 million in Series D convertible preferred stock. This amends a previous agreement for $25 million, with $7.5 million already raised in an initial tranche and an additional $2.5 million committed for a second tranche closing.
Viper Energy and its subsidiary VNOM Holding Company LLC adopted a distribution reinvestment plan (OpCo DRIP) allowing OpCo Unit holders to reinvest cash distributions into newly issued units. Participating holders, including Diamondback Energy, Inc., will receive one share of Class B common stock for each OpCo Unit issued, with the total issuance capped at approximately 72.2 million units.
Benchmark 2026-B44 Mortgage Trust Capital Raise of $777M
Benchmark 2026-B44 Mortgage Trust entered into agreements to sell $701.9 million of publicly offered certificates and $74.8 million of privately offered certificates to a group of underwriters and initial purchasers. The transaction involves the issuance of commercial mortgage pass-through certificates secured by a pool of mortgage loans, with a closing date expected on or about November 20, 2026.
Archrock Signs $450M M&A Deal with HiVolt Energy Holdings, LLC
Archrock, Inc. has entered into a definitive agreement to acquire HiVolt Energy Holdings, LLC for an aggregate value of up to $450 million, consisting of $415 million in cash at closing and $35 million in potential earnout incentives. The acquisition integrates HiVolt's prime power microgrid infrastructure with Archrock's natural gas compression business to expand its energy infrastructure offerings. The transaction is expected to close in the first quarter of 2027, subject to regulatory approvals and customary closing conditions.
Value
$450M
Counterparty
HiVolt Energy Holdings, LLC
“Combining HiVolt’s proven prime power microgrid platform with Archrock's natural gas compression offerings will transform our company into a broader provider of energy infrastructure.”
Brad Childers, President and Chief Executive Officer of Archrock
“HiVolt has built a proven, differentiated platform in the energy microgrid market that complements our core compression business and will enable us to provide additional essential services to customers across the energy value chain, particularly in power-constrained geographies.”
Brad Childers, President and Chief Executive Officer of Archrock
Centerspace M&A Deal with Independence Realty Trust, Inc.
Centerspace shareholders and Independence Realty Trust (IRT) stockholders approved the previously announced merger between the two multifamily REITs. Upon closing, Centerspace shareholders will receive 3.800 shares of IRT common stock for each share owned. The deal remains subject to remaining closing conditions, including lender consents for certain mortgage loans.
Hyundai Auto Receivables Trust 2026-D Capital Raise
Hyundai Auto Receivables Trust 2026-D completed the issuance and sale of several classes of asset-backed notes on November 10, 2026. The transaction involved the transfer of retail installment sale contracts for automobiles from Hyundai Capital America to the trust vehicle. This filing formalizes the definitive agreements, including the Indenture and Sale and Servicing Agreement, related to the securitization.
Hagerty announced the commencement of an underwritten secondary public offering of 9,000,000 shares of its Class A common stock by Hagerty Holding Corp. The selling stockholder also intends to grant underwriters a 30-day option to purchase up to an additional 1,350,000 shares. Hagerty will not receive any proceeds from the sale, as the net proceeds will be used by the selling stockholder to redeem shares for the benefit of the Kim Hagerty Revocable Trust.
National Healthcare Properties Divestiture for $531M
National Healthcare Properties is filing pro forma financial information regarding its probable $531.4 million sale of a 40-facility outpatient medical portfolio to an unaffiliated third party. The filing also accounts for the aggregate impact of 24 completed and 8 probable acquisitions of senior housing operating portfolio (SHOP) communities. The divestiture is expected to close in the fourth quarter of 2026.
NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.
NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.
Value
$820M
Counterparty
Avere Therapeutics, Inc.
“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”
GEN Restaurant Group Divestiture to Chubby Group, Inc. for $100M
GEN Restaurant Group signed a binding letter of intent to sell the operations of 47 U.S. GEN Korean BBQ restaurants to Chubby Group for up to $100 million. The transaction marks a strategic shift to a pure-play Korean CPG company, with GEN retaining brand ownership and its CPG business while transitioning restaurant operations in four phases over 12 months.
Value
$100M
Counterparty
Chubby Group, Inc.
Term
12 months
“In many ways, the third quarter marked the beginning of a new GEN. With our binding letter of intent with Chubby Group signed and definitive agreements under negotiation, we are moving to monetize the restaurant operations we spent fifteen years building, while our shareholders retain full ownership of the GEN brand and our rapidly growing CPG business.”
KLX Energy Services Holdings Signs $16.7M M&A Deal with Wolf Pack Rentals, LLC
KLX Energy Services Holdings, Inc. provided pro forma financial statements following its acquisition of assets from Wolf Pack Rentals, LLC for $16.7 million. The deal, which closed on June 2, 2026, was funded with $14.1 million in cash at closing and $2.7 million in deferred payments (net present value) payable in cash or stock. The filing provides unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2026, to reflect the impact of the acquisition.
Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.